TMZ + E7016
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Wild Type BRAF Stage IV Melanoma
Conditions
Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma
Trial Timeline
May 1, 2012 → Feb 1, 2014
NCT ID
NCT01605162About TMZ + E7016
TMZ + E7016 is a phase 2 stage product being developed by Eisai for Wild Type BRAF Stage IV Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01605162. Target conditions include Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01605162 | Phase 2 | Terminated |
Competing Products
5 competing products in Wild Type BRAF Stage IV Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGM097 | Novartis | Phase 1 | 33 |
| Cobimetinib + Atezolizumab + Pembrolizumab | Roche | Phase 3 | 77 |
| Epirubicine, Oxaliplatin, Capecitabine, Panitumumab | Amgen | Phase 2 | 51 |
| Regorafenib + Temozolomide | Bayer | Phase 1 | 30 |
| STAT3 Inhibitor WP1066 | Moleculin Biotech | Phase 2 | 44 |